Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (125)	1/4/1998 2:46:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 550

Angiogenic VEGF have several extracellular/intracellular receptors which upon protein stimulation (binding to protein and activating signal mechanism) proceed with auto-phosphorylation and further with signal induction in to intercellular level. SU101 is , among others, inhibitor of the PFGF-R activity which means that it inhibit this receptor auto-phosphorylation and have regulatory effects. In last two patents SUGN describe that SU101 and some class of molecules have also inhibitory activity for PDGF-R related kinases: Flt and KDR. This kinases are VEGF receptors. So, latest positive data from SU101 cancer trials may be explained with this additional SU101 activity, and not solely by PDGF-R inhibition. mz